CTMSS

Clinical Outcomes Comparing MST and ECT in Patients with Depression
2026-07-07 20:00 - 21:00 UTC
> >Register Now <<
Speaker: Daniel M. Blumberger, MD, MSc, FRCPC, FCTMSS
This presentation will present data from a large confirmatory efficacy trial of Magnetic Seizure Therapy in unipolar Depression and a smaller trial in patients with Bipolar Depression.
This treatment utilizes transcranial magnetic stimulation to induce a brief seizure with the hope of inducing similar clinical benefit without cognitive adverse effects of ECT.
Key learning objectives include:

Review the background and rationale for studying MST and ECT in the treatment of depression.
Understand the methodology and design of the CREST and CORRECT-BD trials.
Evaluate the efficacy, safety, tolerability, and clinical implications of MST as a potential treatment for TRD.

One CME credit is available. CE Language
Take advantage of our live Q&A session at the conclusion of the webinar.
*Registered attendees will receive access to the on-demand video recording by Friday, July 10, 2026. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar.
When:
USA - July 7, 2026 at 8:00pm ET | 5:00pm PT
UK- July 8, 2026 at 1:00am BST
Australia- July 8, 2026 at 10:00am AEST
Cost:
Member: $25
Trainee Member: FREE
Non-Member: $50
> >Register Now <<
About the Speaker

Daniel M. Blumberger, MD, MSc, FRCPC, FCTMSS

Dr. Blumberger is a Senior Scientist in the Campbell Family Mental Health Research Institute at Centre for Addiction and Mental Health and a subspecialist in geriatric psychiatry. He is the Temerty Chair in Therapeutic Brain Intervention and the Scientific Director of the Temerty Centre for Therapeutic Brain Intervention. He is the Chief of the General Adult Psychiatry and Health Systems Division at CAMH and is a Professor in the Department of Psychiatry at the University of Toronto. He is the Provincial Clinical Lead for Neurostimulation Procedure for Ontario Health.
His primary area of research focuses on clinical intervention trials of neurostimulation and other novel treatments for depression across the lifespan.
He is the principal or co-investigator on multiple clinical trials using different interventional psychiatry modalities including: psilocybin assisted psychotherapy, IV ketamine, electroconvulsive therapy (ECT), magnetic seizure therapy (MST), repetitive transcranial magnetic stimulation (rTMS) and transcranial direct current stimulation (tDCS).

CTMSS 14th Annual Meeting
2026-06-04 - 2026-06-06

Pain Academy Boston
2026-06-04

PULSES Boston
2026-06-03 - 2026-06-04
Course Overview
This in-depth training course offers a Certificate of Completion and features lectures and over 3 hours of hands-on training delivered by Clinical TMS Society renowned clinicians, engineers, and researchers, along with special guests. Attendees will receive current, historical, and practical knowledge for treating patients with TMS based on the best available evidence.
The Program Includes:

A review of the clinical studies that serve as the foundation for treatment of TMS for depression, as well as clinically applicable research and current important studies.
Four lectures on the practical administration of TMS for patients, including practice setup to patient dosing, scheduling, and management.
A review of protocols for TMS: high frequency, theta-burst, low frequency, bilateral, alternative brain targets, rescue treatment, and maintenance treatment.
A revised lecture on TMS risks and their prevention and management, including seizure protocol review.
Hands-on training on coil location placement & motor threshold determination with multiple TMS devices.
A review of promising indications beyond depression, including, obsessive compulsive disorder, smoking cessation, migraine, post-traumatic stress disorder, anxiety, and pain.
An extended Q&A Panel with all PULSES faculty and special guests.

MORE DETAILS COMING SOON... Sign up for updates on when CTMSS opens PULSES registration...

Combined Occipital and Trigeminal Afferent Stimulation for Depression: Findings from the Randomized Controlled Trial and the New ProLiv Home-Use Neuromodulation Device
2026-05-05 20:00 - 21:00 UTC
> >Register Now <<
Speaker: Linda Carpenter, MD
Earlier this year, the FDA approved a novel home-use device for treatment of major depressive disorder in patients who have not responded to antidepressant medication. Available only with a prescription, Proliv™Rx is a wearable, at-home neurostimulation headset that uses non-invasive electrical pulses to stimulate the occipital and trigeminal nerves through surface electrodes.
Dr. Carpenter was the lead Principal Investigator for the large randomized controlled trial that generated efficacy and safety data for this device. She will present the data and describe how the ProLiv device will be used in future clinical practice.
Key learning objectives include:

Evaluate the clinical trial data supporting efficacy and safety of a new home-use device for treatment of Major Depressive Disorder (MDD).
Describe external combined occipital and trigeminal stimulation as a novel mechanism of action in the field of therapeutic neuromodulation.
Discuss how the ProLiv Rx device is incorporated into clinical care as an adjunct therapy for MDD.

One CME credit is available. CE Language
Take advantage of our live Q&A session at the conclusion of the webinar.
*Registered attendees will receive access to the on-demand video recording by Friday, May 8, 2026. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar.
When:
USA - May 5, 2026 at 8:00pm ET | 5:00pm PT
UK- May 6, 2026 at 1:00am BST
Australia- May 6, 2026 at 10:00am AEST
Cost:
Member: $25
Trainee Member: FREE
Non-Member: $50
> >Register Now <<
About the Speaker

Linda Carpenter, MD
Dr. Carpenter has had nearly three decades of externally funded research focused on understanding biomarkers of early life stress and developing new treatments. She has expertise in clinical trials research involving pharmacotherapy and device-based neuromodulation treatments and has been PI on multiple industry- and NIH-funded randomized clinical trials, evaluating the safety and efficacy of both drug- and device-based therapies for depression and anxiety disorders. She has also conducted studies examining various mechanisms of therapeutic action and biomarkers of risk for psychiatric disorders.
For the past two decades, Dr. Carpenter's primary research focus has included therapeutic brain stimulation, and she has led numerous studies examining the efficacy, safety, and mechanisms of VNS, DBS, tDCS, TMS, and other neuromodulation devices in clinical populations.
Dr. Carpenter recently led the multi-center investigation of Proliv, a novel, FDA-cleared home-use device that delivers electrical trigeminal/occipital nerve stimulation for depression, and she is lead PI for a trial that uses fMRI-EEG-based neurofeedback for self-neuromodulation of a targeted depression circuit.
For the past 5 years Dr. Carpenter has also been developing methods for sustaining TMS antidepressant response over time with maintenance treatment and ecological momentary assessment.
Dr. Carpenter is the current Director of the CTMSS’s PULSES training course, and she serves on multiple other CTMSS committees.

Marketing & Promotion of Off-Label Uses of Repetitive TMS Treatment (rTMS)
2026-04-07 20:00 - 21:00 UTC
> >Register Now <<
Speaker: Lindsay Oberman, PhD
This talk will review the Pro’s and Cons of off-label use of TMS. Dr. Oberman will then discuss the FDA clearance process and what indications are considered “off-label”. Finally, she will discuss the legal and ethical considerations for marketing and promoting off-label uses of TMS.
Key learning objectives include:

Gain awareness of what indications are "on label" versus "off label."
Gain awareness of federal regulations regarding marketing and promotion of FDA cleared devices.
Gain understanding of ethical considerations regarding marketing and use of rTMS off-label.

One CME credit is available. CE Language
Take advantage of our live Q&A session at the conclusion of the webinar.
*Registered attendees will receive access to the on-demand video recording by Friday, April 10, 2026. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar.
When:
USA - April 7, 2026 at 8:00pm ET | 5:00pm PT
UK- April 8, 2026 at 1:00am BST
Australia- April 8, 2026 at 10:00am AEST
Cost:
Member: $25
Trainee Member: FREE
Non-Member: $50
> >Register Now <<
About the Speaker

Lindsay Oberman, PhD
Dr. Lindsay Oberman received her PhD from UCSD in Experimental Psychology in 2007. Since that time, she has published over 80 peer-reviewed articles. She has gained international attention for pioneering the use of Repetitive Transcranial Magnetic Stimulation (rTMS) in complex neurodevelopmental and neuropsychiatric disorders including autism, mood disorders, and traumatic brain injury. Dr. Oberman’s research involves the use of an experimental therapeutics approach applying neuroimaging and neurophysiological measures to identify dysfunctional neural circuitry associated with specific transdiagnostic behavioral domains such as mood regulation, sensory processing, social cognition, and executive functioning across disorders. In doing so, she is able to develop novel individualized rTMS treatment protocols that are informed by functional brain network organization. She is currently a Staff Scientist and Directs the Developmental Clinical Neurophysiology and Neurostimulation Research Program within the National Institute of Mental Health Intramural Research Program.

CTMSS Training Singapore: PULSES & Pain Academy
2026-03-07 - 2026-03-08

Accelerated TMS for Depression: Does Imaging Matter?
2026-03-03 20:00 - 21:00 UTC
> >Register Now <<
Speaker: Joseph J. Taylor, MD, PhD
Neuroimaging is common in psychiatric research but rarely applied in psychiatric practice, even for brain stimulation treatments like transcranial magnetic stimulation (TMS). Recently, neuroimaging was used to target TMS during a condensed or “accelerated” treatment protocol. Known as Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT), this intervention resulted in rapid and substantial antidepressant benefits. However, it remains unclear if neuroimaging is necessary for the rapid and substantial antidepressant benefits of accelerated TMS. This question is important to answer because neuroimaging adds cost and complexity to TMS. Here, we will present data from the first head-to-head trial of accelerated TMS with and without imaging guidance for treatment-resistant depression.
Key learning objectives include:

Describe the development of accelerated TMS.
Outline the five ways that the Cole et al protocol (branded SAINT) differs from conventional iTMS.
Summarize the results of this trial comparing imaging-versus scalp-based targeting of accelerated TMS.

One CME credit is available. CE Language
Take advantage of our live Q&A session at the conclusion of the webinar.
*Registered attendees will receive access to the on-demand video recording by Friday, March 6, 2026. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar.
When:
USA - March 3, 2026 at 8:00pm ET | 5:00pm PT
UK- March 4, 2026 at 1:00am GMT
Australia- March 4, 2026 at 12:00pm AEDT
Cost:
Member: $25
Trainee Member: FREE
Non-Member: $50
> >Register Now <<
About the Speaker

Joseph J. Taylor, MD, PhD
Dr. Taylor is an Assistant Professor of Psychiatry at Harvard Medical School. At Brigham and Women’s Hospital, he is the Medical Director of TMS and the Director of Clinical Trials in the Center for Brain Circuit Therapeutics, the Director of the Interventional Psychiatry Research Program, and the Associate Program Director and Research Track Co-Director of the Psychiatry Residency Program. Dr. Taylor’s has expertise in interventional psychiatry, an emerging subspecialty in which procedural treatments are used for psychiatric illnesses that have not improved with routine psychotherapy and medications. Most of his research focuses on deriving and testing brain circuit targets for brain stimulation or neurosurgical ablation. Throughout his career, Dr. Taylor has received funding from the Howard Hughes Medical Institute, the National institutes of Health, the Sidney R. Baer, Jr. Foundation, the Baszucki Group, the Brain and Behavioral Research Foundation, Mass General Brigham, and Harvard Medical School.

TMS for Schizophrenia
2026-02-03 20:00 - 21:00 (Asia/Dubai)
> >Register Now <<
Speaker: Roscoe Brady, PhD, MD
In this presentation we will review the use of TMS for treating symptoms of schizophrenia as well as its use as a research tool to understand schizophrenia pathophysiology. We will discuss symptoms such as medication refractory hallucinations, negative symptoms, and cognitive dysfunction. We will review different approaches including targets derived from both structural and functional neuroanatomy. Finally, we will talk about future directions in treatment including the use of TMS for schizophrenia related comorbidity.
Key learning objectives include:

Summarize the history of TMS trials for medication resistant symptoms of schizophrenia.
Describe how TMS is used as a research tool for understanding schizophrenia pathology.
Describe future directions for TMS trials both for treating schizophrenia symptoms as well as schizophrenia related comorbidity.

One CME credit is available. CE Language
Take advantage of our live Q&A session at the conclusion of the webinar.
*Registered attendees will receive access to the on-demand video recording by Friday, February 6, 2026. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar.
When:
USA - February 3, 2026 at 8:00pm ET | 5:00pm PT
UK- February 4, 2026 at 1:00am GMT
Australia- February 4, 2026 at 12:00pm AEDT
Cost:
Member: $25
Trainee Member: FREE
Non-Member: $50
> >Register Now <<
About the Speaker

Roscoe Brady
Roscoe Brady MD, PhD is a board-certified psychiatrist and neuroscientist. He is the Vice-Chair for Research in the Department of Psychiatry at Beth Israel Deaconess Medical Center and an Associate Professor at Harvard Medical School. He is also the director of the Research Concentration in the Beth Israel Deaconess Medical Center Harvard Psychiatry Residency Training Program. He is the recipient of the Jonathan F. Borus Outstanding Early Educator Award and Stuart T. Hauser Mentorship Award from Harvard Medical School. His research focus is developing neuromodulation treatments for medication resistant symptoms of psychotic disorders. He is the Principal Investigator of multiple NIMH R01 funded clinical trials.

Single-Day Regimens for TMS: Recent Progress and Open Questions *Free Session*
2026-01-06 20:00 - 21:00 UTC
Kick off the year with complimentary Grand Rounds!
> >Register Now <<
Speaker: Jonathan Downar, MD, PhD, FRCPC
Improving access to TMS is a priority for practitioners and patients alike. Multi-day treatment protocols pose a significant logistical barrier to access for many patients, especially those in remote areas.
Recently, proof-of-concept studies have begun to investigate the effectiveness of single-day TMS regimens. Here we review the development of single-day TMS protocols, along with relevant studies on potential mechanisms. We consider new data on the outcomes of single-day TMS in various applications. We examine possible refinements of the approach to improve practicality, tolerability, and effectiveness. We consider important outstanding questions requiring future research on this novel but potentially quite impactful approach to TMS treatment.
Key learning objectives include:

Review rationale, mechanisms, and history of development of single-day TMS protocols.
Review recent progress in refining single-day TMS protocols and comparative outcomes vs. conventional once-daily protocols.
Review outstanding questions facing future developments and refinement of single-day TMS protocols.

Take advantage of our live Q&A session at the conclusion of the webinar.
*Registered attendees will receive access to the on-demand video recording by Friday, January 9, 2026. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar.
When:
USA - January 6, 2026 at 8:00pm ET | 5:00pm PT
UK- January 7, 2026 at 1:00am GMT
Australia- January 7, 2026 at 12:00pm AEDT
Cost:
Member: FREE
Trainee Member: FREE
Non-Member: FREE
*CME not available for this session.
> >Register Now <<
About the Speaker

Jonathan Downar, MD, PhD, FRCPC
Dr Jonathan Downar is an Adjunct Professor in the Department of Psychiatry and Institute of Medical Science at the University of Toronto. He holds a clinical appointment at the Centre for Addiction and Mental Health in Toronto. He holds a PhD in functional neuroimaging from the University of Toronto, trained in medicine at the University of Calgary, and completed his psychiatry residency at the University of Toronto.
Dr Downar has published over 180 peer-reviewed articles on TMS and brain imaging, in journals including Lancet, JAMA Psychiatry, Nature Medicine, Nature Neuroscience, and Brain Stimulation. He is the senior author of the THREE-D study, a major Canadian TMS study published in Lancet in 2018 that demonstrated that TMS treatments could be reduced from 38 min sessions to 3 minute sessions with no loss of efficacy. He has also pioneered the use of novel TMS protocols including dorsomedial TMS and orbitofrontal TMS in depression and in other clinical disorders.
He is currently working to develop novel protocols that improve the practicality and economics of TMS, with the goal of achieving cost parity with pharmacotherapy and universal access to this powerful treatment.

First Principles of TMS Induced Synaptic Plasticity and Potential Impact on Clinical Outcomes
2025-12-02 20:00 - 21:00 UTC
> >Register Now <<
Speaker: Alex McGirr, MD, PhD, FRCPC
Transcranial magnetic stimulation is delivered in patterns of pulses that are informed by pre-clinical electrophysiology to induce changes at the level of the synapse. Our delivery of this treatment is agnostic to two major confounds that influence the ability of synaptic weights to change in response to stimulation:
a) disease processes limiting plasticity
b) concurrent pharmacology
This grand rounds will review clinically relevant implications of these, and the emerging space using pharmacological adjuvants to enhance the effects of stimulation and its relation to clinical outcomes.
Key learning objectives include:

Explain the mechanisms of transcranial magnetic stimulation (TMS), inclucing how pulse patterns influence synaptic plasticity and the role of electrophysiological principles.
Identify factors that affect synaptic responsiveness to TMS, such as disease-related limitations in plasticity and the impact of concurrent pharmacological treatments.
Discuss the clinical implications of combining TMS with pharmacological adjuvants, including how these interactions can enhance stimulation effects and influence clinical outcomes.

One CME credit is available. CE Language
Take advantage of our live Q&A session at the conclusion of the webinar.
*Registered attendees will receive access to the on-demand video recording by Friday, December 5, 2025. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar.
When:
USA - December 2, 2025 at 8:00pm ET | 5:00pm PT
UK- December 3, 2025 at 1:00am GMT
Australia- December 3, 2025 at 12:00pm AEDT
Cost:
Member: $25
Trainee Member: FREE
Non-Member: $50
> >Register Now <<
About the Speaker

Alexander McGirr, MD, PhD, FRCPC
Dr. Alexander McGirr is a psychiatrist and clinician scientist at the University of Calgary, Canada. He trained across major Canadian institutions, including
McGill University (undergraduate and masters of neuroscience), the University of Toronto (MD), and the University of British Columbia (psychiatry residency
and PhD neuroscience). His clinical work and research focuses on mood disorders, circuit dissection, and non-invasive neurostimulation as both a means
of probing the brain and inducing changes in neural circuits underlying pathology. Although his research program includes both basic science and
clinical arms, the focus of this ground rounds will be clinical.

The RECOVER Trial of Vagus Nerve Stimulation in Markedly Treatment-Resistant Depression: Critical Findings, Lessons Learned, Future Directions
2025-10-07 20:00 - 21:00 UTC
> >Register Now <<
Speaker: Scott T. Aaronson, MD
The RECOVER study is a large randomized sham controlled study of vagus nerve stimulation in markedly treatment resistant depression involving 1000 participants. The first papers for the unipolar cohort have been published and submitted to the Centers for Medicare and Medicaid for re-consideration for coverage. This presentation will review the extensive database, the important lessons learned about studying severely treatment resistant depression and anticipate possible future availability of this novel therapy.
Key learning objectives include:

Identify how to improve assessment of patient outcomes in severely treatment resistant depression.
Recognize patient presentations with increased likelihood of benefit from vagus nerve stimulation.
Describe the proposed mechanism of action for vagus nerve stimulation in treating depression.

Take advantage of our live Q&A session at the conclusion of the webinar.
One CME credit is available. CE Language
*Registered attendees will receive access to the on-demand video recording by Friday, October 10, 2025. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar.
When:
USA - October 7, 2025 at 8:00pm ET | 5:00pm PT
UK- October 8, 2025 at 1:00am BST
Australia- October 8, 2025 at 10:00am AEDT
Cost:
Member: $25
Trainee Member: FREE
Non-Member: $50
> >Register Now <<
About the Speaker

Scott T. Aaronson, MD
Dr. Scott Aaronson is a thought leader in the areas of biological psychiatry, diagnosis, and the integration of somatic and psychological therapies. He is an adjunct professor of psychiatry at the University of Maryland School of Medicine, distinguished life fellow of the American Psychiatric Association, and is a fellow of the American College of Psychiatrists, the Clinical TMS Society and the American Society for Clinical Psychopharmacology. Dr. Aaronson also serves on the board of the American Society for Clinical Psychopharmacology. He graduated with honors from Harvard Medical School and completed his psychiatric residency at McLean Hospital.
Dr. Aaronson is the Chief Science Officer for the Institute for Advanced Diagnostics and Therapeutics at Sheppard Pratt. He has been involved with the development of new strategies to alleviate the symptoms in treatment resistant mood disorders, and has published numerous articles on his research including pivotal studies in the use of devices—Transcranial Magnetic Stimulation (TMS), Vagus Nerve Stimulation (VNS) and psychedelics in the treatment of severe refractory mood disorders. His paper on a five year observational study of VNS in treatment resistant depression published in 2017 in the American Journal of Psychiatry led to the Centers for Medicare and Medicaid supporting a randomized clinical trial of VNS in unipolar and bipolar depression through their Coverage with Evidence Development Program. He is on the committee that developed this study and is now in the process of publishing the results from the unipolar arm in a series of articles.

PULSES
2025-09-26 - 2025-09-28
This in-depth training course offers a certificate of completion and features lectures and over 3 hours of hands-on training delivered by Clinical TMS Society renowned clinicians, engineers, and researchers and some special guests. Attendees will receive current, historical, and practical knowledge for treating patients with TMS based on the best evidence.
The program includes:

An introduction to the history of and basic scientific principles of TMS by Professor Anthony Barker, who designed the first-ever TMS machine in 1985;
A review of the clinical studies that serve as the foundation for treatment of TMS for depression, as well as clinically applicable research and current important studies;
Four lectures on the practical administration of TMS for patients, including practice setup to patient dosing, scheduling, and management;
A review of protocols for TMS: high frequency, theta-burst, low frequency, bilateral, alternative brain targets, rescue treatment, maintenance treatment;
A lecture on TMS risks and their prevention and management, including seizure protocol review;
Hands-on training on targeting, coil placement, and motor threshold determination with multiple TMS devices;
A review of promising indications beyond depression, including, obsessive compulsive disorder, smoking cessation, migraine, post-traumatic stress disorder, anxiety, and pain; and
A special track with lectures and hands-on training tailed for TMS technicians; and
An extended Q & A Panel with all PULSES faculty and special guests.

After completion of the course, the clinician will have obtained a historical, current, and practical knowledge of the scientific basis for treating psychiatric patients with TMS. Technicians will have additional skills needed for daily patient assessment, monitoring, and administration of stimulation.
Attendees will also have the ability to participate in an interactive Q&A Panel with Pulses faculty. Those who complete the course are awarded a certificate of completion.
Date/Time: 26-28 September 2025 | 9:00 am to 6:00 pm (PT) (time is subject to change)
Location: Providence, Rhode island | Butler Hospital | 345 Blackstone Blvd, Providence, RI 02906
CLICK HERE FOR MORE INFORMATION

TMS for Stroke Rehabilitation
2025-09-02 20:00 - 21:00 UTC
> >Register Now <<
Join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: TMS for Stroke Rehabilitation
Speaker: Dylan J. Edwards, PhD
The first demonstration of transcranial magnetic stimulation (TMS) occurred nearly 40 years ago, and it showed that TMS could readily activate the human cortex without sophisticated targeting. However, as a tool to probe and modify cortical function, TMS has historically been limited by imprecise targeting. With new advances, including neuronavigation and contemporary modeling of cortical electric field distribution, we are now able to use TMS to examine the detailed functional organization of the primary motor cortex, as well as how the cortex is reorganized after the brain is lesioned. In research to date, patient responses to TMS have been variable, and inaccurate targeting may be a key factor contributing to the high variability in response rate to repetitive TMS (rTMS) interventions. The precision of TMS targeting will be discussed in the context of neurorehabilitation and motor recovery.
Key learning objectives include:

Describe the rationale for using TMS in recovery of motor function after damage to the cortico-spinal tract such as in stroke or spinal cord injury.
Describe the benefit of electric field modeling in estimating optimal treatment intensity.
State the principal result of at least one rTMS/neurorecovery RCT over the past decade.

Take advantage of our live Q&A session at the conclusion of the webinar.
One CME credit is available. CE Language
*Registered attendees will receive access to the on-demand video recording by Friday, September 8, 2025. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar.
When:
USA - September 2, 2025 at 8:00pm ET | 5:00pm PT
UK- September 3, 2025 at 1:00am BST
Australia- September 3, 2025 at 10:00am AEST
Cost:
Member: $25
Trainee Member: FREE
Non-Member: $50
> >Register Now <<
About the Speaker

Dylan J. Edwards, PhD
Dr. Dylan J. Edwards is the Nancy Wachtel Shrier Director of Jefferson Moss Rehabilitation Research Institute, Director of the Human Motor Recovery Laboratory at the Institute, Professor in the Department of Rehabilitation Medicine at The Sidney Kimmel Medical College at Thomas Jefferson University, and Adjunct Professor of Neuroscience and Director of the NeuroRehabilitation and Robotics Laboratory at Edith Cowan University. He is dedicated to translating basic science findings in neurologically healthy people to develop and evaluate novel, clinically-relevant approaches for neurological assessment and neurorehabilitation in stroke and spinal cord injury using non-invasive stimulation, neuromodulation, robotics, combinatorial therapies, neuroimaging, and telerehabilitation.

Neuroimaging to Enhance Precision in Clinical Trials
2025-08-05 20:00 - 21:00 UTC
> >Register Now <<
Join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: Neuroimaging to Enhance Precision in Clinical Trials
Speaker: Aristotle Voineskos, MD, PhD, FRCPC
This Grand Rounds explores how the upcoming use of neuroimaging is being used to better direct clinical care. This session discusses precision medicine, implementation strategies, and learning health systems to deliver more targeted, evidence-based treatments. The content is grounded in high-impact, peer reviewed literature to ensure scientific rigor.
Key learning objectives include:

Design considerations for imaging in trials.
Considerations for precision imaging in trials.
Emerging applications of precision imaging in trials.

Take advantage of our live Q&A session at the conclusion of the webinar.
One CME credit is available. CE Language
*Registered attendees will receive access to the on-demand video recording by Monday, August 11, 2025. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar.
When:
USA - August 5, 2026 at 8:00pm ET | 5:00pm PT
UK- August 6, 2026 at 1:00am BST
Australia- August 6, 2025 at 10:00am AEST
Cost:
Member: $25
Trainee Member: FREE
Non-Member: $50
> >Register Now <<
About the Speaker
Aristotle Voineskos, MD, PhD, FRCPC
Dr. Aristotle Voineskos is the Senior Vice President, Research and Science & Director of the Campbell Family Mental Health Research Institute at the Centre for Addiction and Mental Health (CAMH). At both CAMH and the University Health Network (UHN), he serves as the joint Vice President for the CAMH-UHN Partnership. Dr. Voineskos earned his MD and PhD at the University of Toronto, and completed a research fellowship at Brigham and Women’s Hospital, Harvard Medical School. Dr. Voineskos is a Professor of Psychiatry at the
Temerty Faculty of Medicine. He is an internationally recognized researcher, physician, and leader, who has been dedicated to helping people suffering from severe mental illness and brain disorders.
Dr. Voineskos has served in progressive clinical and research leadership roles across his career. In these roles, he has significantly improved access to care, reduced wait times, and implemented and scaled evidence-based care models across the health system. Most recently as Vice President Research at CAMH, he helped grow the research enterprise substantially, via key pillars of equity, training and evaluation, clinical-research integration, open science, digital transformation, and sustainability. He is known for driving innovation and enhancing team performance. As joint Vice President of the CAMH-UHN Partnership, he helps lead the work across executive teams to deliver comprehensive physical and mental health care for patients, and accelerate advancements in brain health sciences.
Dr. Voineskos has published over 300 papers many of which are in the leading journals of psychiatry, neurology, medicine, and neuroscience. He has won numerous awards for his research and mentorship including the A.E. Bennett Award for Clinical/Translational Research from the Society of Biological Psychiatry (SOBP) in 2022 and the Joel Elkes Research Award from the American College of Neuropsychopharmacology (ACNP) in 2024.

Grand Rounds Webinar: Advocating for TMS Coverage: An International Perspective
2025-07-01 20:00 - 21:00 (America/New_York) | Zoom
> >Register Now <<
Join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: Advocating for TMS Coverage: An International Perspective
Speakers: Carlene MacMillan, MD, FCTMSS, DFAACAP and Shelly Weiss Lahn, BS, CRA
Join leaders from the Clinical TMS Society for a global exploration of insurance coverage for Transcranial Magnetic Stimulation. This session will share insights from a survey of international CTMSS members, expert interviews, and a review of global reimbursement models. Learn how clinicians around the world are successfully advocating for broader TMS access—and gain practical strategies to advance coverage in your own region.
Key learning objectives include:

Identify key differences in insurance coverage policies for TMS across international healthcare systems.
Analyze effective advocacy strategies used by clinicians and organizations to expand TMS access globally.
Apply insights from international case studies to develop tailored approaches for improving TMS coverage in participants' local contexts.

Take advantage of our live Q&A session at the conclusion of the webinar.
One CME credit is available. CE Language
*Registered attendees will receive access to the on-demand video recording by Monday, July 7, 2025. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar.
When:
USA - July 1, 2026 at 8:00pm ET | 5:00pm PT
UK- July 2, 2026 at 1:00am BST
Australia- July 2, 2026 at 10:00am AEST
Cost:
Member: $25
Trainee Member: FREE
Non-Member: $50
> >Register Now <<
About the Speakers
Carlene MacMillan MD, FCTMSS, DFAACAP
Dr. Carlene MacMillan is the co-chair of the Clinical TMS Society Insurance Committee and the Member-at-Large on the Executive Committee. She is also on the board of the Foundation for the Advancement of Clinical TMS. She is board-certified in adult and child psychiatry. Dr.MacMillan is the Chief Product Officer at Radial, a network of interventional practices.

Shelly Weiss Lahn BS, CRA
Shelly Weiss Lahn is the co-chair of the Clinical TMS Society Insurance Committee. She is the CEO of Neuro Wellness TMS Centers of America in Coral Springs, Florida and the owner of Overseas Referral Network of America, an International Medical Concierge Service.

FACTMS: Future Directions in TMS Therapy
2025-06-12 20:00 - 22:00 UTC | San Diego
Future Directions in TMS Therapy
📅 June 12, 2025
🕗 8:00 – 10:00 PM PT
📍 Sheraton San Diego Hotel & Marina, Marisol Room

Dr. Siddiqi Dr. Wiliams

Join FACTMS for a wonderful event during the Clinical TMS Society Annual Meeting. The evening will feature the first Ad Astra Award presentation to Dr. Nolan Williams and Dr. Shan Siddiqi. In addition to an inspiring presentation, enjoy hors d’oeuvres, specialty cocktails and a popular silent auction with vacation packages, TMS memorabilia and other exciting items.

All proceeds benefit the Bob Sammons Clinical TMS Research Grant.
LEARN MORE >

Grand Round Webinar: Research 101: What data can I report from my TMS practice, and how can I report it?
2025-05-06 20:00 - 21:00 (America/New_York) | Zoom
> >Register Now <<
Join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: "Research 101: What data can I report from my TMS practice, and how can I report it?"
Speaker: Andrew F. Leuchter, MD
rTMS is a rapidly growing area of clinical practice. Many practitioners have created innovative approaches to treatment, observed novel findings that could help improve outcomes, or discovered new potential indications for rTMS treatment. This presentation will review the types of data that can be reported in the scientific and clinical literature, how to approach creating a report, and how to find the right "home" for publication.
Key learning objectives include:

Present goals of naturalistic research in TMS practice.
Discuss different types of research report formats.
Consider what constitutes a meaningful contribution to the literature.

Take advantage of our live Q&A session at the conclusion of the webinar.
One CME credit is available. CE Language

*Registered attendees will receive access to the on-demand video recording by Friday, May 9, 2025. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar.
When:
USA - May 6, 2025 at 8:00pm ET | 5:00pm PT
UK- May 7, 2025 at 1:00am BST
Australia- May 7, 2025 at 10:00am AEST
Cost:
Member: $25
Trainee Member: FREE
Non-Member: $50
All Grand Rounds are recorded and available On-Demand. Recordings are available by the Friday after the live event.
> >Register Now <<
About the Speaker: Andrew F. Leuchter, MD
Andrew F. Leuchter, MD, is a Distinguished Professor of Psychiatry and Director of the Neuromodulation Division at UCLA. An expert on the treatment of mood disorders, Dr. Leuchter directs the Transcranial Magnetic Stimulation (TMS) Clinical and Research Service. This is one of
the largest academic TMS program in the country and treats patients with depression, OCD, pain, tinnitus, and other neuropsychiatric illness. His research aims to develop novel treatment strategies and predict which treatments are most likely to benefit individual patients.
Dr. Leuchter has authored over 200 scientific articles on topics including neuromodulation for the treatment of depression, EEG biomarkers to guide treatment of neuropsychiatric illness, and theories of antidepressant action. He teaches internationally on TMS and other neuromodulation methods, and received the 2019 Outstanding Research Mentor Award from the Semel Institute.
Andrew F. Leuchter, MD, is a Distinguished Professor of Psychiatry at the Semel Institute for Neuroscience and Human Behavior, and Director of the Neuromodulation Division at the Semel Institute. An expert on the treatment of mood disorders, Dr. Leuchter directs the Transcranial Magnetic Stimulation (TMS) Clinical and Research Service. This is one of the largest academic TMS programs, performing clinical treatment and translational research across campuses throughout Los Angeles. The dual mission of the Division is to provide care for patients with depression, chronic pain, OCD, tinnitus, and other difficult-to-treat neuropsychiatric illness, as well as enhancing treatment effectiveness, as well as clinical trials to improve treatment of depression, Post-Traumatic Stress Disorder (PTSD), and Attention-Deficit/Hyperactivity Disorder (ADHD). Dr. Leuchter’s research aims to develop novel treatment strategies and uses brain-imaging techniques, such as quantitative electroencephalography (qEEG) and magnetic resonance imaging (MRI) to examine brain function and predict which treatments are most likely to benefit individual patients.
> >Register Now <<

Minding Your Own TMS Business
2025-03-25 20:00 - 21:00 (America/New_York)
📅 March 25, 2025
📍 Virtual
Moderated by Dr. Linda Carpenter, with an all-female panel, including current CTMSS President, Dr. Martha Koo, Dr. Rebecca Allen, Dr. Carlene MacMillan and Dr. Kristin Raj.
$25 Donation. All proceeds benefit the Patient Assistance Fund.
REGISTER NOW >

Pulses - Orlando
2025-03-07 - 2025-03-09 | Omni Orlando Resort at ChampionsGate, 1500 Masters Blvd, Championsgate, FL, United States
This in-depth training course offers a certificate of completion and features lectures and over 2 hours of hands-on training delivered by Clinical TMS Society renowned clinicians, engineers, and researchers and some special guests. Attendees will receive current, historical, and practical knowledge for treating patients with TMS based on the best evidence.
Register Now

Date/Time: Friday March 7, 2025 (4pm ET) - Sunday, March 9, 2025 (3pm ET) (time is subject to change)
Location: The Omni Orlando Resort at ChampionsGate: 1500 Masters Blvd, ChampionsGate, FL 33896
The program includes:
1. An introduction to the history of and basic scientific principles of TMS by Professor Anthony Barker, who designed the first-ever TMS machine in 1985;
2. A review of the clinical studies that serve as the foundation for treatment of TMS for depression, as well as clinically applicable research and current important studies;
3. Four lectures on the practical administration of TMS for patients, including practice setup to patient dosing, scheduling, and management;
4. A review of protocols for TMS: high frequency, theta-burst, low frequency, bilateral, alternative brain targets, rescue treatment, maintenance treatment;
5. A revised lecture on TMS risk and their prevention and management, including seizure protocol review;
6. Hands-on training on coil location placement & motor threshold determination with multiple TMS devices;
7. A review of promising indications beyond depression, including, obsessive compulsive disorder, smoking cessation, migraine, post-traumatic stress disorder, anxiety, and pain; and An extended Q & A Panel with all PULSES faculty and special guests.
8. After completion of the course, the clinician will have obtained a historical, current, and practical knowledge of the scientific basis for treating psychiatric patients with TMS.
Attendees will also have the ability to participate in an interactive Q&A Panel with Pulses faculty. Those who complete the course are awarded a certificate of completion.
Cancellation Policy:
Conference registration cancellations must be received in writing on or before February 1, 2025, to receive a refund minus a $100.00 administration fee.
Conference registration may not be transfered to a future conference.
No refunds will be issued for cancellations received after February 1, 2025.
In the event CTMSS must cancel the conference due to unforeseen circumstances, CTMSS will refund the cost of registration. However, CTMSS does not assume responsibility for any additional costs, charges, or expenses; to include, charges made for travel and lodging

Practical Ethics for TMS Practices
2025-03-04 20:00 - 21:00 (America/New_York) | Zoom
> >Register Now <<
Join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: "Practical Ethics for TMS Practices"
Speaker: Ian Cook, MD, DLFAPA, FCTMSS
Ethical issues arise every day when providing TMS therapy, whether around professionalism, boundaries, transparency, or conflicts of interest. Interactions with patients, manufacturers, colleagues, and the public may challenge us and members of our care teams. Fortunately, there are frameworks that can help us identify the issues and guide our approaches so we can uphold professional standards.
Using illustrative case vignettes, in this webinar we'll explore the ethical challenges in TMS practice with Dr. Ian Cook, long-time co-chair of the CTMSS Legal, Business, and Ethics Committee, and a Member of our Board.
During this presentation, attendees will address these three key topic areas:

Professionalism
Boundaries
Transparency and Conflicts of Interest

Take advantage of our live Q&A session at the conclusion of the webinar.
One CME credit is available.
CE Language
*Registered attendees will receive access to the on-demand video recording by Friday, Friday, March 7, 2025. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar.
When:
USA - March 4, 2025 at 8:00pm EST | 5:00pm PST
UK- March 5, 2025 at 1:00am GMT
Australia- March 5, 2025 at 12:00pm AEDT
Cost: Members: $25 | Non-members $50 | Trainee Members FREE
> >Register Now <<
Ian Cook, MD, DLFAPA, FCTMSS

Dr. Ian A. Cook is the founding Director and CEO of the Los Angeles TMS Institute and a Professor Emeritus of Psychiatry and of Bioengineering at UCLA. His career has largely focused on improving the treatment of mental illnesses by working at the interface between medicine and technology.
In his 25+ year academic career at UCLA, he started the Unipolar Depression Research and Clinic Program, held an endowed chair in Depression Research, treated the first patient in his UCLA TMS Treatment Service in March 2009, and served as a member of the rTMS Task Group of the National Network of Depression Centers. He was Chief of Staff at UCLA’s Neuropsychiatric Hospital and was elected Chair of the Faculty of the David Geffen School of Medicine. He also was appointed Chief Translational Innovation Officer for the Semel Institute for Neuroscience and Human Behavior.
For many years he was a member of the Executive Committee on Practice Guidelines of the American Psychiatric Association, helping guide their dissemination of evidence-based practices in psychiatry. Nationally, he also served as a standing member of the NIH’s ITVA Review Committee (“Interventions Committee for Adult Disorders”).
He left UCLA in 2018 to start the Los Angeles TMS Institute and bring advanced treatment modalities out of the laboratory and into clinical care in Southern California.
Dr. Cook received his undergraduate degree in engineering from Princeton University and graduated from the Yale School of Medicine before coming to UCLA for his residency training. He then completed an NIMH T32 Research Fellowship before joining the UCLA faculty.
He is a Distinguished Life Fellow of the American Psychiatric Association and one of the inaugural Fellows of the Clinical TMS Society. He joined the Board of the Society in 2013, has been co-chair of its Legal, Business, and Ethics Committee for many years, and received the President’s Award in 2021. He is Vice President and a founding Board Member of the Foundation for the Advancement of Clinical TMS.
> >Register Now <<

Grand Rounds Webinar: Recent Advances in Neurotherapeutics for Child and Adolescent Mood Disorders
2025-02-04 08:00 - 20:00 (America/New_York) | Zoom
> >Register Now <<
Join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: "Recent Advances in Neurotherapeutics for Child and Adolescent
Mood Disorders"
Speaker: Paul E. Croarkin, DO, MS
Join Dr. Croarkin for an update on the clinical implementation and research of transcranial magnetic stimulation for adolescents with depression. Dr. Croarkin will also review recent, ongoing, and planned research focused on neurotherapeutics.
At the end of the presentation, attendees will:

Demonstrate a working knowledge of noninvasive brain stimulation modalities such as transcranial electrical stimulation, transcranial magnetic stimulation, and electroconvulsive therapy.
Demonstrate the ability to discuss recent studies adapting transcranial magnetic stimulation for adolescents with major depressive disorder.
Demonstrate the ability to discuss recent research with ketamine in adolescents and to discuss potential future studies and related challenges with psychedelic therapeutic.

Take advantage of our live Q&A session at the conclusion of the webinar.
*Registered attendees will receive access to the on-demand video recording by Friday, Friday, February 7, 2025. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar.
One hour CME credit is available - Click here for CE Language
When:
USA - February 4, 2025 at 8:00pm EST | 5:00pm PST
UK- February 5, 2025 at 1:00am
GMT
Australia- February 5, 2025 at
12:00pm AEDT
Cost:
Member: $25
Trainee Member: FREE
Non-Member: $50
All Grand Rounds are recorded and available On-Demand. Recordings are available by the Friday after the live event.
> >Register Now <<
About the Speaker: Paul Croarkin, DO, MS

Dr. Croarkin is the Ervin A. and Margaret C. Mueller Director of the Children’s Research Center at Mayo Clinic and the Chair for Pediatric
Research in the Department of Pediatrics and Adolescent Medicine. He is a professor of Psychiatry, Pediatrics, and Pharmacology in the Mayo Clinic College of Medicine and Science. He serves as the Editor-in-Chief for the Journal of Child and Adolescent Psychopharmacloogy.
Dr. Croarkin completed medical school at the University of North Texas Health Science Center. He then completed residency training in psychiatry at Naval Medical Center San Diego, where he served as chief resident. Following this, Dr. Croarkin served as a US Navy psychiatrist in an academic role at Walter Reed Army Medical Center and in an operational setting as a psychiatrist embedded with the 24th Marine Expeditionary Unit in North Babil during Operation Iraqi Freedom. He returned for clinical and research training in child
and adolescent psychiatry at UT Southwestern Medical Center in Dallas, again serving as chief resident. He earned a Master of Science degree with distinction in clinical science from the Graduate School of Biomedical Sciences at UT Southwestern Medical Center. Thereafter, he joined the Mayo Clinic Department of Psychiatry and Psychology.
An expert in child, adolescent, and adult mood disorders, neurotherapeutics, and psychopharmacology, Dr. Croarkin conducts research to develop innovative diagnostic and treatment approaches for children and adolescents. His research has been funded by the National Alliance for Research on Schizophrenia and Depression, the National Institutes of Health, and industry partnerships. His team focuses on adapting and innovating neurotherapeutics for youth with psychiatric disorders while studying GABAergic and glutamatergic
neurotransmission. These efforts have informed and supported the clinical implementation of transcranial magnetic stimulation interventions for adolescents with depression. His findings have been published in numerous peer-reviewed journals, including The Journal of the American Academy Child and Adolescent Psychiatry, JAMA Psychiatry, and Neuropsychopharmacology.
> >Register Now <<

Grand Rounds Webinar: "Oops, I did it again": TMS as a Tool to Promote Sobriety and Decrease Drug and Alcohol Relapse
2025-01-07 20:00 - 21:00 (America/Los_Angeles) | Zoom
> >Register Now <<
Join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: "Oops, I did it again": TMS as a Tool to Promote Sobriety and Decrease Drug and Alcohol Relapse.
Speaker: Colleen A. Hanlon, PhD
Join us for an insightful session on Transcranial Magnetic Stimulation (TMS) as an innovative treatment for addiction. This session will explore the FDA approved use of TMS for smoking cessation, European clearance for stimulant use disorder, and emerging evidence supporting its application in alcohol use disorders. Learn about the mechanisms of action, current clinical research, and practical strategies for integrating TMS into your addiction treatment protocols. Designed for physicians and mental health providers, this session will provide valuable insights into how TMS can enhance patient outcomes and expand treatment options for substance use disorders.
At the end of the presentation, attendees will:
- Identify the current FDA indication for TMS in smoking cessation and discuss the emerging evidence supporting its use in stimulant and alcohol use disorders.
- Describe the mechanisms of action of TMS in the treatment of addiction and how it modulates brain activity to reduce substance use.
- Evaluate the mechanisms of action of TMS in the treatment of addiction and how it modulates brain activity to reduce substance use.
Take advantage of our live Q&A session at the conclusion of the webinar.
*Registered attendees will receive access to the on-demand video recording by Friday, January 10, 2025. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar.
One hour CME credit is available - Click here for CE Language
When:
USA - January 7, 2025 at 8:00pm EST | 5:00pm PST
UK- January 8, 2025 at 1:00am GMT
Australia- January 8, 2025 at 12:00pm AEDT
Cost:
Member: $25
Trainee Member: FREE
Non-Member: $50
All Grand Rounds are recorded and available On-Demand. Recordings are available by the Friday after the live event.
> >Register Now <<
About the Speaker: Colleen A. Hanlon, PhD

Vice President, Medical Affairs, BrainsWay
Professor (adjunct), Wake Forest University School of Medicine
Dr. Hanlon is an internationally recognized thought-leader in the development and expansion of non-invasive neuromodulation therapeutics for new populations.
She is currently serving as the Vice President of Medical Affairs for BrainsWay and Director of their Innovation Team. Before coming to BrainsWay she was a tenured professor at the Wake Forest School of Medicine. There she ran a multidisciplinary research program devoted to developing brain-circuit based interventions for individuals struggling with drug and alcohol use disorders. She has nearly 20 years of clinical research experience in transcranial magnetic stimulation (TMS) and brain imaging. Recognized as a pioneer int TMS for addiction, Dr. Hanlon received over $12 million in National Institute of Health funding, led over 15 clinical studies of TMS, published over 100 peer-reviewed publications, and mentored over 75 trainees in brain imaging and TMS.
She received her undergraduate degree from the University of Florida, a Ph.D. in neurobiology from Duke University wherein she focused on motor recovery after stroke and in Parkinsons Disease using functional MRI. She did a postdoctoral fellowship at Wake Forest University wherein she first became interested in neuromodulation.
In 2023, she was given the prestigious International Brain Stimulation Early Career Investigator award and she is the senior author on the first “Consensus Paper” published by a group of over 70 scientists from over 10 countries outlining the path forward for Non-Invasive Therapeutic Development for Addiction.
In addition to advancing the science and evidence for TMS for various indications, she also participates in the research training and education community at local, national, and international levels. She has directed the Advanced TMS Training Course sponsored by the National Center for Neuromodulation for Rehabilitation and has served on the grassroots Advocacy committee and Public Policy committees of several scientific organizations devoted to expanding access to care for individuals with drug and alcohol use disorders.

> >Register Now <<

Non-Invasive Brain Stimulation to Treat Chronic Pain Targets, Mechanisms and Clinical Outcomes
2024-11-12 12:00 - 13:00 (America/New_York)
> >Watch Now <<
You are invited to join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series, Non-Invasive Brain Stimulation to Treat Chronic Pain Targets, Mechanisms and Clinical Outcomes, presented by Daniel Ciampi de Andrade, MD, PhD.
Dr. Daniel Ciampi de Andrade is a clinical neurologist currently focused on teaching and doing research on chronic pain. He has a strong interest on the use of rTMS for the management of neurological diseases, chronic pain in particular. As rTMS enter guidelines for the managements of chronic pain, Dr. Daniel Ciampi de Andrade will provide an update on the mechanisms of action of rTMS for pain management, and how it can be used to aid people with chronic pain in their quest for adequate pain relief.
At the end of this presentation, attendees will:

Have a clear understanding on how chronic pain syndromes are classified.
Have a general knowledge of the treatment options for the most common pain syndromes.
Understand how neuromodulation, in particular rTMS, can be added to the treatment plan as backed up by evidence.

Take advantage of our live Q&A session at the conclusion of the webinar.
One hour CME credit is available - Click here for CE Language
Date/Time:
USA - November 12, 2024 at 12:00pm EST | 9:00am PST
UK- November 12, 2024 at 5:00pm GMT
Australia- November 13, 2024 at 4:00am AEDT
Format: Live Webinar
Cost: Members: $25 | Non-members $50 | Trainee Members FREE
Can't make this time and date? All Grand Rounds are recorded and available On-Demand to all registered attendees. Recordings are available Friday after the live event.

Speaker: Daniel Ciampi de Andrade, MD, PhD

Dr. Daniel Ciampi de Andrade is an associate professor and researcher at the Center of Neuroplasticity and Pain, Department of Health Science and technology and Faculty of Medicine, Aalborg University, Denmark.
Dr. Daniel Ciampi de Andrade trained as a clinical neurologist at the University of Sao Paulo, Brazil, and in France (Université Paris-Saclay /Université Paris XII). He trained with Didier Bouhassira, Nadine Attal and Jean-Pascal Lefaucheur during his stay in Paris, France, coming back to Sao Paulo, Brazil in 2009. He then was appointed coordinator of the Multidisciplinary Pain Center of the Neurology Department, at the University of Sao Paulo. This center was founded by his mentor, Professor Manoel Jacobsen Teixeira, in 1974 and is one of the largest pain centers in Latin America. Dr. Daniel Ciampi de Andrade co-founded and was vice chair of the Medical Research Laboratory of “invasive neuroscience” from 2019 to 2021.
In 2021 he moved to Aalborg and joined CNAP. His research has been focused on pain in neurological diseases and neuromodulation for pain relief. In particular, he has performed research on how pain can influence cortical connectivity and how this information can be used to inform personalized treatment approaches.
Dr. Daniel Ciampi de Andrade has been serving as Vice-Chair of EFIC´s Research Committee since 2024, section editor of the European Journal of Pain since 2016, and advisory Board of Pain Reports since 2018. He as published more than 180 peer-reviewed studies, along with pain book editing and several international book chapters. He received a European Research Council grant that will allow him to continue research, paired with an amazing team of colleagues at CNAP, to further explore the effects of pain in the human brain.
> >Watch Now <<

When
November 12th, 2024 from 9:00 AM to 10:00 AM

Location

United States

Contact

Phone: info@clinicaltmssociety.org
Email: info@clinicaltmssociety.org

Event Fee(s)

Fee Level

Webinar Registration | Member
$25.00

Webinar Registration | Non-Member
$50.00

Webinar Registration | Student
$0.00

Webinar Registration | Associate Member
$25.00

Speaker Price
-$50.00

CTMSS On-Demand Webinar: An Introduction to TMS
2024-11-07 08:00 - 17:00 UTC
>>WATCH NOW<<
*NEWLY UPDATED* CTMSS On-Demand Webinar: An Introduction to TMS
Release Date: January 1, 2023
Expiration Date: December 31, 2024
The Clinical TMS Society is offering a 4 part on-demand webinar focused on the introduction to TMS.
CTMSS On-Demand Webinar: An Introduction to TMS is geared primarily for new clinicians and TMS operators/technicians. In addition, experienced clinicians and technicians who seek a stronger knowledge base would also benefit from the review and updates.
Participants will learn:

the history of rTMS, including a knowledge of indications, clinical efficacy, review of data;
a review of the significant scientific literature giving rise to the technology's adoption;
an understanding of practical office implementation;
a review of the evidence for conditions other than depression

Format: On-Demand Webinar
Cost:

CTMSS Members | $150 USD
Non-members | $300 USD

You will receive immediate access to the video.

Presenters:

Debra Stultz, MD, FCTMSS
Dr. Debra J. Stultz is the Director and Owner of Stultz Sleep and Behavioral Health in Barboursville, West Virginia. Dr. Stultz earned her medical degree from Marshall University School of Medicine in Huntington, West Virginia. She completed a residency in psychiatry and a fellowship in child/adolescent psychiatry through West Virginia University at their Charleston Division through Charleston Area Medical Center in Charleston, West Virginia. She is board certified in psychiatry, sleep medicine, and behavioral sleep medicine. With a special interest in Narcolepsy, she treats a variety of sleep disorders and psychiatric issues. Her specialty in psychiatry is treatment-resistant depression. She is also the editor for the Clinical TMS Society Newsletter, on their Board of Directors, Co-Chair of the Education Committee, and the chairman of the TMS and Sleep Disorders Affinity Group.

Jonathan Becker, DO
Dr. Becker completed his undergraduate and Masters degrees in Developmental Psychology at Tulane University in New Orleans before attending Des Moines University for medical school. He completed his psychiatry residency program at Vanderbilt University and served as a faculty member there for 7 years. While at Vanderbilt, Dr. Becker served as the medical director of the neuromodulation service from 2017 – 2022. He joined the Neuroscience and TMS Treatment Center in Brentwood, TN in January 2021. He is an active member of the Clinical TMS Society and a member of the Education Committee.

Nicholas Mischel, MD, PhD
Dr. Mischel is an Assistant Professor and Director of Interventional Psychiatry and Neuromodulation Research at Wayne University School of Medicine, in their Department of Psychiatry and Behavioral Neurosciences. He completed his psychiatry residency at Duke University Medical Center, focusing on brain stimulation clinical/translational research. He now focuses on medication-resistant mood disorders using rTMS and rapid-acting antidepressant medication infusions. He is a member of the Clinical TMS society and is on the Outreach and Education Committees.
Sandeep Vaishnavi, MD, PhD
Dr. Vaishnavi received his medical degree from the University of Alabama at Birmingham and completed his residency at Duke University. He completed a visiting fellowship in Transcranial Magnetic Stimulation at Duke University. He is an Adjunct Associate with the Department of Medicine-Pulmonary at Duke University, is a faculty member with the Duke Visiting Fellowship program in Transcranial Magnetic Stimulation, is a member of the faculty network for the Duke Institute for Brain Sciences, is Director of Mindpath Care Centers Clinical Trails Institute, and a member of the Corporate Governance Board for MindPath Care Centers. He is a member of Clinical TMS Society and is on the Education Committee.

Residents, Trainee Doctors, & Medical Students | CTMSS Education Slide Deck: Transcranial Magnetic Stimulation (TMS) - An Introduction
2024-11-07
>>WATCH NOW<<
Learning objectives:
Part 1: TMS in Depression

Understand the evidence for transcranial magnetic stimulation (TMS) as a treatment for depression
Describe where TMS falls in a major depressive disorder (MDD) treatment algorithm
Know the history of TMS
Understand potential mechanisms of actions of TMS
Know the efficacy rate of TMS for MDD from scientific literature

Part 2: Beyond Depression

Know FDA cleared psychiatric indications for TMS
Understand the basic neurobiology of OCD and addictions as related to the potential mechanism of TMS
Review the data supporting the use of TMS for OCD and smoking cessation
Identify the potential risks of TMS
Understand patient appropriateness for TMS based on demographics, diagnosis, and treatment history

Cost: Free
Please register to view the presentation. On-demand video will populate at the bottom of this page once registered. To access the powerpoint presentation slide deck, you must also complete the Education Slide Deck Member User Agreement. At the bottom of this recording you will be prompted to complete a brief survey.

Speakers: Kristin Raj, MD & Suzanne Kerns, MD
Dr. Raj specializes in the treatment of mood disorders with expertise in neuromodulation and in the psychopharmacological management of the bipolar disorder. She is Chief of Interventional Psychiatry and Chief of the Bipolar Clinic at Stanford University. She is the director of education for interventional psychiatry where she manages resident and fellow education in brain stimulation and the development of didactics. She is also director of the neuroscience curriculum for the psychiatry residency where she has worked to create and assess a new series of interactive lectures. She trained in biomedical engineering in undergraduate at Case Western Reserve University and completed her medical degree and psychiatry residency at Stanford University. She currently serves on the Board of Directors and the Education Committee of the Clinical TMS Society.
Dr. Kerns completed her undergraduate studies at the University of North Carolina in Chapel Hill. She attended medical school at the University of Sydney in Australia, followed by a psychiatry residency at Duke University Medical Center. Dr. Kerns subsequently completed a year-long Fellowship in Brain Stimulation at the Medical University of South Carolina (MUSC) under the guidance of Dr. Mark George, a founding father of TMS. After several years of private practice at Seattle Neuropsychiatric Treatment Center with a faculty appointment at the University of Washington, she returned to MUSC, where she is now an Assistant Professor of Psychiatry on the Brain Stimulation Service. Dr. Kerns is a past member of the Board of Directors of the Clinical TMS Society, past Member-at-Large on the CTMSS Executive Committee, past Co-Chair of the CTMSS Education Committee, and she continues to proudly serve as a member of the Education Committee and Resident Education Task Force for the Clinical TMS Society.

If you have any questions, please email: info@clinicaltmssociety.org

On-Demand Webinars Library
2024-10-21 | Zoom

Apples and Oranges: Comparative Effectiveness Research in TMS
2024-10-01 08:00 - 17:00 UTC | Zoom
> > Register Now <<
Although not labeled as such by the FDA, TMS is considered a third line treatment by many practitioners and health insurance company policies. Earlier referral to TMS is not commonly practiced but may be non-inferior to or superior to medication switches or augmentation. Our field lacked trials that compared different modalities of treatment in parallel with TMS until recently, which is the subject of this webinar.
The core aspect of this webinar will be reviewing two very recent articles that compare TMS to antidepressant medications. We will also review basic concepts of non-inferiority trials and meta-analyses.
At the end of the presentation, attendees will be able to:

Understand "head-to-head" trials and meta-analyses research.
Review and understand recent comparative articles on TMS.
Review and understand the current and future placement of TMS in the treatment algorithms of depression.

Format: On Demand Webinar
Cost: Members: $25 | Non-members $50 | Trainee Members FREE
Speaker: Mehmet Dokucu, D, PhD, DFAPA

Dr. Dokucu is a broadly trained neuroscientist (PhD) and academic psychiatrist (MD) with expertise in Electroconvulsive Therapy, Transcranial Magnetic Stimulation, Consultation Liaison Psychiatry and Psycho-oncology. He was the founding director of the Transcranial Magnetic Stimulation program at Northwestern Medicine in Chicago. He is currently an Associate Professor of Psychiatry at Dartmouth Geisel School of Medicine and he currently directs the Mood Disorders and Interventional Psychiatry Program at Dartmouth Hitchcock Medical Center.
> > Register Now <<

September 10, 2024 Town Hall Member Meeting
2024-09-10
Join the Clinical TMS Society President Martha Koo, MD, FAPA, FASAM, FCTMSS, committee co-chairs, and other Society volunteers for an update on current activities.
This is your opportunity to learn more about the Society's various goals and projects.
>>MEMBER WATCH NOW<<

Stimulating for Hope: Transcranial Magnetic Stimulation for Patients at Risk for Suicide
2024-09-03 08:00 - 09:00 UTC
> > Register Now <<

The United States is in the midst of a crisis of suicide, and TMS providers often must confront this directly. In this presentation, Dr. Philip will provide a brief overview of the existing TMS protocols used to reduce suicidal ideation, reviewing their efficacy and also burden of administration. He will describe an ongoing clinical trial combining TMS plus psychotherapy for PTSD, and outline his own clinical approach to treating suicidal patients, so that attendees can consider how they can address this critically important issue.
At the end of the presentation, attendees will be able to:

Describe various evidence-based TMS parameters to treating patients at higher suicide risk.
Demonstrate understanding of the interaction (or lack thereof) between changes in depression and suicidal ideation during TMS.
Discuss future TMS options in high risk patients.

Format: On-Demand Webinar
Cost: Members: $25 | Non-members $50 | Student Members FREE
Speaker: Noah S. Philip, MD

Dr. Philip is a Professor of Psychiatry and Human Behavior at the Alpert Medical School of Brown University. He is the founding Section Chief of Psychiatric Neuromodulation at VA Providence, and is Lead for Mental Health Research at the VA RR&D Center for Neurorestoration and Neurotechnology.
Dr. Philip received his BSc from McGill University and his MD from Albany Medical College where he graduated AOA and with a Distinction in the Study of Biomedical Ethics. He completed his psychiatry residency training at Brown University, followed by T32 and Neuromodulation Fellowships at Brown.
Dr. Philip’s laboratory uses a precision approach to new and emerging technologies, with the goal to understand and treat posttraumatic stress disorder, major depression, and suicidality. His research has been featured in JAMA Psychiatry, American Journal of Psychiatry, Biological Psychiatry, and the National Neuroscience Curriculum Initiative (tDCS+Virtual Reality for PTSD). He is currently conducting an NIMH-funded cooperative study to perform a first-in-human study investigating MRI-guided low intensity focused ultrasound for depression and anxiety (U01 MH123427).
Dr. Philip has received awards and recognition from the American Psychiatric Association, Society for Biological Psychiatry, American College of Neuropsychopharmacology, and others. He has been funded through grants from the VA (Rehabilitation, Clinical Science, and Health Services R&D), NIMH, NIDA, Department of Defense, and through industry and small-business collaborations. He is active in several national organizations, including SOBP and ACNP, and is a past President of the Psychiatric Research Society.
Dr. Philip plays a significant training and mentoring role at Brown, where he is Associate Director of the NIMH R25 psychiatry resident research training program, and serves as a mentor through national organizations such as the Career Development Institute for Psychiatry. He is committed to action to improve diversity, equity, inclusion, and belonging.

> > Register Now <<
